Core Scientific, Inc.

CORZ · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders3.1%

Institutions119.7%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2021-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$65.42M	$24.38M	–
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$281.12M	$389.60M	–
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	$37.90M	$121.07M	–
Gross profit as a percentage of revenue.	57.9%	496.6%	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$245.59M	-$19.20M	-$5.21M
Operating income as a percentage of revenue.	-375.4%	-78.7%	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$288.62M	-$1.32B	-$32.50M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-0.88	$-4.39	$-0.83
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-0.88	$-4.39	–

Balance Sheet

	2025-12-31	2024-12-31	2021-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$311.38M	$836.20M	$970876
Everything the company owns that has value — cash, property, inventory, investments, and more.	$2.35B	$1.60B	$346.37M
All of the company's interest-bearing borrowings, short and long term combined.	–	$16.29M	–
Everything the company owes — debt, unpaid bills, and other obligations.	$3.31B	$2.42B	$65.58M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$962.74M	-$820.18M	-$64.21M

Cash Flow Statement

	2025-12-31	2024-12-31	2021-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$278.25M	$42.90M	-$1.87M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$729.00M	$94.96M	–
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$450.75M	-$52.06M	–

	You	Peer avg
P/E	–	34.7
Revenue Growth	+108.8%	+5.5%
ROE	–	14.1%

Core Scientific, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison